Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 3/20 | 0.67 |
| ▸ | HTR3A | P46098 | 1/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 13/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.50 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6328956 | 0.81 | HTR4 (0.66) | HTR4 | |
| SCHEMBL6327502 | 0.81 | HTR4 (0.58) | HTR4 | |
| SCHEMBL6333842 | 0.81 | HTR4 (0.58) | HTR4 | |
| SCHEMBL6329052 | 0.81 | HTR4 (0.60) | HTR4 | |
| SCHEMBL1502177 | 0.81 | CHEK1 (0.44) | HTR4HTR3ADRD2 | |
| Hydrochloric Acid SCHEMBL6329100 | 0.80 | HTR4 (0.65) | HTR4 | |
| SCHEMBL6328871 | 0.80 | KDM4E (0.53) | HTR4DRD2 | |
| SCHEMBL7260087 | 0.80 | HTR4 (0.57) | HTR4HTR3ACHRM1CHRM2CHRM4 | |
| SCHEMBL725669 | 0.80 | HTR4 (1.00) | HTR4HTR3ADRD2 | |
| Hydrochloric Acid SCHEMBL7035321 | 0.79 | HTR4 (0.98) | HTR4HTR3ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6979690-B2 | Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators | PFIZER INC. (US) | 2005-12-27 | — | — | US | disclosed |
| US-20030207875-A1 | Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators | PFIZER INC | 2003-11-06 | — | — | US | disclosed |
| WO-2003057688-A2 | OXO OR OXY-PYRIDINE COMPOUNDS AS 5-HT4 RECEPTOR MODULATORS | PFIZER JAPAN INC. (JP) | 2003-07-17 | — | — | WO | disclosed |
| EP-1325921-A2 | Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators | Pfizer Inc. (US) | 2003-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207875-A1 | Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators | HRH4, HRH2, HTR4 | HTR4 3/4885HTR3A 72/4885CHRM1 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.